Journal of Hepatology
Volume 53, Issue 6 , Pages 1000-1005 , December 2010

Individualized treatment with combination of Peg-interferon alpha 2b and ribavirin in patients infected with HCV genotype 3

  • Alessandra Mangia

      Affiliations

    • Liver Unit, IRCCS, “Casa Sollievo della Sofferenza” Hospital, San Giovanni Rotondo, Italy
    • Corresponding Author InformationCorresponding author. Address: Liver Unit, IRCCS “Casa Sollievo della Sofferenza” Hospital, 71013 San Giovanni Rotondo, Italy. Tel.: +39 882416270; fax: +39 882416271.
    • ,
  • Franco Bandiera

      Affiliations

    • Internal Medicine, Hospital Sassari, Italy
    • ,
  • Giuseppe Montalto

      Affiliations

    • Internal Medicine, University of Palermo, Palermo, Italy
    • ,
  • Leonardo Mottola

      Affiliations

    • Liver Unit, IRCCS, “Casa Sollievo della Sofferenza” Hospital, San Giovanni Rotondo, Italy
    • ,
  • Valeria Piazzolla

      Affiliations

    • Liver Unit, IRCCS, “Casa Sollievo della Sofferenza” Hospital, San Giovanni Rotondo, Italy
    • ,
  • Nicola Minerva

      Affiliations

    • Internal Medicine, Hospital Canosa, Italy
    • ,
  • Adriano Pellicelli

      Affiliations

    • Gastroenterology Hospital “S. Camillo”, Rome, Italy
    • ,
  • Giovanni L. Ricci

      Affiliations

    • Internal Medicine, University “La Sapienza”, Rome, Italy
    • ,
  • Marina Cela

      Affiliations

    • Gastroenterology, Ospedali Riuniti, Foggia, Italy
    • ,
  • Vito Carretta

      Affiliations

    • Internal Medicine, Hospital Venosa, Italy
    • ,
  • Gaetano Scotto

      Affiliations

    • Infectious Disease, University of Foggia, Foggia, Italy
    • ,
  • Donato Bacca

      Affiliations

    • Internal Medicine, Hospital Casarano, Italy
    • ,
  • Brigida Annicchiarico

      Affiliations

    • Internal Medicine, Catholic University, Rome, Italy
    • ,
  • Mario Romano

      Affiliations

    • Internal Medicine, Hospital “S. Pertini”, Rome, Italy
    • ,
  • Maurizio Russello

      Affiliations

    • Internal Medicine, Hospital “G. Garibaldi” Catania, Italy
    • ,
  • Giorgio Barbarini

      Affiliations

    • Infectious Disease, IRCCS, Policlinico S. Matteo, Pavia, Italy
    • ,
  • Ernesto Agostinacchio

      Affiliations

    • Internal Medicine, Clinica Santa Rita, Bari, Italy
    • ,
  • Angelo Andriulli

      Affiliations

    • Gastroenterology Division, IRCCS, “Casa Sollievo della Sofferenza” Hospital, San Giovanni Rotondo, Italy

Received 15 March 2010 ,Revised 13 April 2010 ,Accepted 29 April 2010.

References 

  1. Zeuzem S, Teuber G, Lee JH, Ruster B, Roth WK. Risk factors for the transmission of hepatitis C. J Hepatol. 1996;24:3–10
  2. Lauer GM, Walker BD. Hepatitis C virus infection. N Engl J Med. 2001;34:41–52
  3. Asselah T, Rubbia-Brandt L, Marcellin P, Negro F. Steatosis in chronic hepatitis C: why does it really matter?. Gut. 2006;55:123–130
  4. Adinolfi LE, Gambardella M, Andreana A, Tripodi MF, Utili R, Ruggiero G. Steatosis accelerates the progression of liver damage of chronic hepatitis C patients and correlates with specific HCV genotype and visceral obesity. Hepatology. 2001;33:1358–1364
  5. Leandro G, Mangia A, Hui J, Fabris P, Rubbia-Brandt L, Colloredo G, et al. Relationship between steatosis, inflammation, and fibrosis in chronic hepatitis C: a meta-analysis of individual patient data. Gastroenterology. 2006;130:1346–1362
  6. Bochud PY, Cai T, Overbeck K, Bochud M, Dufur JF, Mullhaupt B, et al. Genotype 3 is associated with accelerated fibrosis progression in chronic hepatitis C. J Hepatol. 2009;51:655–666
  7. Andriulli A, Leandro G, Mangia A, Iacobellis A, Ippolito A, Zeuzem S. Meta-analysis: the outcome of antiviral therapy in HCV genotype 2 and genotype 3 patients with chronic hepatitis. Aliment Pharmacol Ther. 2008;28:397–404
  8. Foster GB, Hezode C, Bronowicki JP, Carosi G, Weiland O, Verlinden L, et al. Activity of telaprevir alone or in combination with peginterferon alfa-2a and ribavirin in treatment-naïve genotype 2 and 3 hepatitis C patients. Interim results of study C209. J Hepatol. 2009;50:S22
  9. Benhamou Y, Moussalli J, Ratziu V, Lebray P, Gysen V, de Backer K, et al. Results of a proof of concept study (C210) of telaprevir monotherapy and in combination with peginterferon alfa-2a and ribavirin in treatment naïve genotype 4 HCV patients. J Hepatol. 2009;50:S6
  10. Manns M, Foster GR, Rockstroh JK, Zeuzem S, Zoulim F, Houghton M. The way forward in HCV treatment: finding the right path. Nat Rev Drug Discov. 2007;6:991–1000
  11. Dienstag JL, McHutchison JG. American Gastroenterology Association technical review on the management of hepatitis C. Gastroenterology. 2006;130:225–230
  12. Ghany MG, Strader DB, Thomas DL, Seef LB. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology. 2009;49:1335–1374
  13. Berg T, Von Wagner M, Nasser S, Sarrazin C, Heintges T, Gerlach T, et al. Extended treatment duration for hepatitis C virus type 1: comparing 48 versus 72 weeks of PegInterferon alfa 2a plus ribavirin. Gastroenterology. 2006;130:1086–1097
  14. Sanchéz-Tapias J, Diago M, Escartin P, Enriquez J, Romero-Gomes M, Barcena R, et al. Peginterferon alfa 2a plus ribavirin for 48 versus 72 weeks in patients with detectable hepatitis C virus RNA at week 4 of treatment. Gastroenterology. 2006;131:451–460
  15. Jacobson IM, Brown RS, Freilich B, Afdhal N, Kwo PY, Santoro J, et al. WIN-R Study Group. Peginterferon alfa-2b and weight-based or flat-dose ribavirin in chronic hepatitis C patients: a randomized trial. Hepatology. 2007;46:971–981
  16. Wai CT, Greenson JK, Fontana RJ, Kalbfleish JD, Marrero JA, Conjeevaram HS, et al. A simple non invasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology. 2003;38:518–526
  17. Mangia A, Dalgard O, Verbaan H, Scotto G, Bacca D, Agostinacchio E, et al. Ribavirn dosage in HCV genotypes 2 and 3 patients completing short therapy with peg-interferon alfa-2b and ribavirin. Aliment Pharmacol Ther. 2010;[Epub ahead of print]
  18. Mangia A, Santoro R, Minerva N, Ricci GL, Carretta V, Persico M, et al. Peginterferon alfa-2b and ribavirin for 12 vs 24 weeks in HCV genotype 2 or 3. N Engl J Med. 2005;352:2609–2617
  19. Dalgard O, Bjoro K, Ring-Larsen H, Bjornsson E, Holberg-Petersen M, Skovlnd E, et al. Pegylated interferon alfa and ribavirin for 14 versus 24 weeks in patients with Hepatitis C virus genotype 2 or 3 and rapid virological response. Hepatology. 2008;47:35–43
  20. Berg T, Weich V, Teuber G, Klinker H, Moller B, Rasenack J, et al. Individualized treatment strategy according to early viral kinetics in hepatitis C virus type 1-infected patients. Hepatology. 2009;50:369–377
  21. Mangia A, Minerva N, Bacca D, Cozzolongo R, Ricci GL, Carretta V, et al. Individualized treatment duration for hepatitis C genotype 1 patients: a randomized controlled trial. Hepatology. 2008;47:43–50
  22. Drusano GL, Preston SL. A 48-week duration of therapy with pegylated interferon alpha 2b plus ribavirin may be too short to maximize long term response among patient infected with genotype 1 hepatitis virus. J Infect Dis. 2004;189:964–970
  23. Di Martino V, Richou C, Thevenot T, Sanchez-Tapiaz J, Ferenci P. Modulations of peg-interferon plus ribavirin duration according to HCV-genotype and virologic response at week 4 and week 12: meta-analyse of RCTs with individual data. Hepatology. 2008;48:213
  24. Slavenburg S, Weggelaar I, van Oijen MGH, Derenth JP. Optimal length of antiviral therapy in patients with hepatitis C virus genotype 2 and 3: a meta-analysis. J Hepatol. 2009;50:S237
  25. Hadziyannis SJ, Sette H, Morgan TR, Balan V, Diago M, Marcellin P, et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med. 2004;140:346–355
  26. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Gonzales FL, et al. Peginterferon alfa2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med. 2002;347:975–982
  27. Aghemo A, Rumi MG, Soffredini R, D’Ambrosio R, Ronchi G, Del Ninno E, et al. Impaired response to interferon-alpha2b plus ribavirin in cirrhotic patients with genotype 3a hepatitis C virus infection. Antivir Ther. 2006;11:797–802
  28. Willems B, Hadziyannis SJ, Morgan TR, Diago M, Marcellin P, Bernstein D, et al. Should treatment with peginterferon plus ribavirin be intensified in patients with HCV genotype 2/3 without a rapid virologic response?. J Hepatol. 2007;46:S6
  29. Powis J, Peltekian M, Lee SS, Sherman M, Bain VG, Cooper C, et al. Exploring differences in response to treatment with peginterferon alpha 2a and ribavirin in chronic hepatitis C between genotypes 2 and 3. J Viral Hepat. 2008;18:52–57
  30. Shiffman ML, Suter F, Bacon BR, Nelson D, Harley H, Solà R, et al. Peginterferon alfa-2a and ribavirin for 16 or 24 weeks in HCV genotype 2 or 3. N Engl J Med. 2007;357:124–134
  31. Bugianesi E, Marchesini G, Gentilcore E, Cua IH, Vanni E, Rizzetto M, et al. Fibrosis in genotype 3 hepatitis C and nonalcoholic fatty liver disease: role of insulin resistance and steatosis. Hepatology. 2006;44:953–955
  32. Walsh MJ, Jonsson JR, Richardson MM, Lipka GM, Purdie DM, Clouston AD, et al. Non-response to antiviral therapy is associated with obesity and increased hepatic expression of suppressor of cytokine signalling 3 (SOCS-3) in patients with chronic hepatitis C, viral genotype 1. Gut. 2006;55:529–535
  33. Zeuzem S, Hultcrantz R, Bourliere M, Goeser T, Marcellin P, Sanchez-Tapias J, et al. Peginterferon alfa-2b plus ribavirin for treatment of chronic hepatitis C in previously untreated patients infected with HCV genotype 2 or 3. J Hepatol. 2004;40:993–999
  34. Mangia A, Thompson A, Santoro R, Piazzolla V, Mottola L, Shianna K, et al. Predictive role of an IL28B polymorphism on SVR and RVR in patients with genotype 2/3 chronic infection. Gastroenterology. 2010;139:821–827

PII: S0168-8278(10)00694-X

doi: 10.1016/j.jhep.2010.04.042

Journal of Hepatology
Volume 53, Issue 6 , Pages 1000-1005 , December 2010

Article Tools

* Image Usage & Resolution